How Pharmacists Could Be Key to Addressing the Opioid Crisis

How Pharmacists Could Be Key to Addressing the Opioid Crisis

Optimal adherence to long-acting injectable buprenorphine (BUP-XR or Sublocade®) for opioid use disorder saves $15,017 per patient annually by drastically reducing costly emergency department visits and detoxification events. This research supports the economic benefits of paying community pharmacists to administer long-acting injections, effectively improving treatment access while lowering overall healthcare spending.

Read More
Landmark Support for Pharmacist-Prescribed Buprenorphine in Minnesota
Michelle Caetano Michelle Caetano

Landmark Support for Pharmacist-Prescribed Buprenorphine in Minnesota

Landmark Support for Pharmacist-Prescribed Buprenorphine in Minnesota

In a major win for low-barrier access to Medications for Opioid Use Disorder (MOUD), the Minnesota Medical Association (MMA) Board of Trustees recently voted unanimously to support legislative efforts that would allow appropriately trained pharmacists to independently initiate, prescribe, and administer buprenorphine.

Read More
No Payment, No Program: What the 2025 Medicaid Summit Means for Pharmacy-Based OUD Treatment
Payment for Clinical Services Michelle Caetano Payment for Clinical Services Michelle Caetano

No Payment, No Program: What the 2025 Medicaid Summit Means for Pharmacy-Based OUD Treatment

Establishing a sustainable model for pharmacist-led clinical services requires more than just clinical expertise—it requires a framework for reimbursement. Based on the fundamental pillars of Infrastructure, Collaboration, and Dedicated Time, this guide explores how pharmacists can successfully navigate Medicaid payment structures.

By aligning these three areas, pharmacies can transition from a product-centered model to a service-oriented one that prioritizes patient outcomes and professional sustainability.

Read More